A new survey of British neurologists shows that no commonly accepted model exists for the diagnosis of conversion disorder. Instead, the results indicate that the neurologist's diagnosis is influenced largely by their communication with the patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Hallett, M. Physiology of psychogenic movement disorders. J. Clin. Neurosci. 17, 959–965 (2010).
Stone, J., Vuilleumier, P. & Friedman, J. H. Conversion disorders: separating “how” from “why.” Neurology 74, 190–191 (2010).
Kanaan, R. A., Armstrong, D. & Wessely, S. C. Neurologists' understanding and management of conversion disorder. J. Neurol. Neurosurg. Psychiatry doi:10.1136/jnnp.2010.233114.
Voon, V. et al. The involuntary nature of conversion disorder. Neurology 74, 223–228 (2010).
LaFrance, W. C. Jr & Friedman, J. H. Cognitive behavioral therapy for psychogenic movement disorder. Mov. Disord. 24, 1856–1857 (2009).
LaFrance, W. C. Jr et al. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav. 14, 591–596 (2009).
Goldstein, L. H. et al. Cognitive-behavioral therapy for psychogenic nonepileptic seizures: a pilot RCT. Neurology 74, 1986–1994 (2010).
Stone, J. et al. FMRI in patients with motor conversion symptoms and controls with simulated weakness. Psychosom. Med. 69, 961–969 (2007).
Esposito, M., Edwards, M. J., Bhatia, K. P., Brown, P. & Cordivari, C. Idiopathic spinal myoclonus: a clinical and neurophysiological assessment of a movement disorder of uncertain origin. Mov. Disord. 24, 2344–2349 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
J. H. Friedman has acted as a consultant for Acadia, EMD Serano, Genzyme and Teva. He has received honoraria from Boehringer Ingelheim, GlaxoSmithKline, Teva and United Biosource. He has also received grants from Acadia, Cephalon, EMD Serano, Teva and United Biosource.
Rights and permissions
About this article
Cite this article
Friedman, J. What do neurologists think about conversion disorder?. Nat Rev Neurol 7, 306–307 (2011). https://doi.org/10.1038/nrneurol.2011.65
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.65
